CTLS

Tevogen Bio to Develop T Cell Therapies for Treatment of Epstein-Barr Virus Related Cancers and Multiple Sclerosis

Retrieved on: 
Thursday, December 1, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, COVID-19, Infectious Diseases, COVID-19, Virology, MS, CTLS, Cell, Cancer, Epstein–Barr virus, Patient, Neurology, M.B.A, Degenerative disease, Genome, EBV, Inflammation, Medicine, Bio, Lymphoma, Nasopharyngeal carcinoma, Multiple sclerosis, Virus, Severe acute respiratory syndrome coronavirus 2, CTL, Infection, Vaccine, Pharmaceutical industry

These CTLs will also be studied for the potential use in EBV-related cancers, such as nasopharyngeal carcinoma and certain lymphomas.

Key Points: 
  • These CTLs will also be studied for the potential use in EBV-related cancers, such as nasopharyngeal carcinoma and certain lymphomas.
  • We believe that cell therapies are expected to be the norm, not the exception, said Tevogen CEO Ryan Saadi , M.D., M.P.H.
  • Tevogen Bio is driven by a team of distinguished scientists and highly experienced biopharmaceutical leaders who have successfully developed and commercialized multiple franchises.
  • This press release contains certain forward-looking statements relating to Tevogen Bio Inc (the Company) and its business.

Tevogen Bio to Study Therapeutic Potential of its Investigational COVID-19 T Cell Therapy in Long COVID

Retrieved on: 
Tuesday, November 22, 2022
Biotechnology, Pharmaceutical, Health, COVID-19, Patient, Omicron, Clinical trial, POC, Cell, Bio, Science, Cancer, Severe acute respiratory syndrome coronavirus 2, Virus, Medicine, COVID, CTLS, CTL, Virology, Genome, Protein, Immunodeficiency, COVID-19, Neurology, TVGN, Hope, Malignancy, Degenerative disease, Pharmaceutical industry, Vaccine, Long COVID, Delta

Tevogen Bio , a late-stage clinical biotechnology company specializing in the development of cellular immunotherapies in oncology, neurology, and virology announced today its intention to study potential therapeutic use of its investigational COVID-19 T cell therapy, TVGN-489, in Long COVID.

Key Points: 
  • Tevogen Bio , a late-stage clinical biotechnology company specializing in the development of cellular immunotherapies in oncology, neurology, and virology announced today its intention to study potential therapeutic use of its investigational COVID-19 T cell therapy, TVGN-489, in Long COVID.
  • The finding that none of the patients in the TVGN 489 Proof-of-Concept (POC) trial, treated for their initial COVID infection, developed Long COVID to date is leading Tevogen to explore the potential of TVGN 489 to also treat Long COVID.
  • Im greatly encouraged by the POC trial experience of TVGN 489 and hopeful that our investigational COVID-19 therapy will eventually offer hope to a substantial segment of Long COVID patients.
  • Anyone that knows someone who has been impacted by this debilitating disease understands the importance of advancing science to alleviate the suffering from Long COVID, said Tevogen CEO Ryan Saadi , M.D., M.P.H.

Tevogen Bio CEO Ryan Saadi and CSO Neal Flomenberg share White House concerns about emerging COVID-19 variants and impact on immunocompromised patients, and express commitment to accelerate development of company’s investigational COVID-19 therapy

Retrieved on: 
Thursday, October 27, 2022
COVID-19, Research, Public Policy, Government, Biotechnology, White House, Federal Government, Health, Pharmaceutical, Science, Public Safety, Protein, Time, CD8, Medicine, Patient, Malignancy, Virus, Cell, Cancer, BQ, Terminology, Bio, Forward-looking statement, Neurology, Industry, COVID-19, Genome, Clinical trial, COVID, Company, Population, Nobel Peace Prize, Degenerative disease, CTL, Research, CEO, Severe acute respiratory syndrome coronavirus 2, Immunodeficiency, Immunity, Virology, Mutation, Therapy, CTLS, Development, Pharmaceutical industry, Vaccine, Delta, Omicron

TVGN-489 is highly purified cytotoxic CD8+ T lymphocytes (CTLs) designed to detect and kill SARS-CoV-2 infected cells.

Key Points: 
  • TVGN-489 is highly purified cytotoxic CD8+ T lymphocytes (CTLs) designed to detect and kill SARS-CoV-2 infected cells.
  • Patients treated were infected with a range of all COVID variants at the time, from Delta through Omicron BA.5.
  • Additionally, each patient had co-morbidities rendering them high risk and 50 percent of those additionally met the definition of being immunocompromised.
  • Its concerning that, so far, all of Omicrons subvariants have shown increased transmissibility and high immune escape potential, said Dr. Neal Flomenberg, Tevogens Chief Scientific Officer.

Equillium Announces Presentation of Data Demonstrating Biological Importance of Multi-Cytokine Inhibitors EQ101 and EQ102 at the La Jolla Immunology Conference

Retrieved on: 
Wednesday, October 26, 2022
Research, Public Relations, Investor Relations, Clinical Trials, Communications, Biotechnology, Pharmaceutical, Health, Science, Oncology, Other Science, CD8, Therapy, Feedback, Technology, SEC, Risk, Conference, MCP, CD4, Cytokine, Degenerative disease, Volunteering, Drug development, IL-6, Biology, Patient, Research, Cell, Granzyme, Nasdaq, Private Securities Litigation Reform Act, Anti-CD3 monoclonal antibody, Alopecia areata, Trial of the century, Safety, CD28, Flow cytometry, CTLS, Forward-looking statement, Itolizumab, NK, Inflammation, EDGAR, Peptide, Autoimmunity, Perforin, JAK, Poster, Pharmaceutical industry, Vaccine

The research highlights the potential for multi-cytokine inhibitors such as EQ101 and EQ102, as potentially effective strategies for the treatment of certain autoimmune diseases.

Key Points: 
  • The research highlights the potential for multi-cytokine inhibitors such as EQ101 and EQ102, as potentially effective strategies for the treatment of certain autoimmune diseases.
  • EQ101 and EQ102 are both first-in-class multi-cytokine inhibitors that provide selective targeting of biological redundancy and synergy at the receptor level, which has significant advantages over other approaches, including JAK inhibition.
  • The results shown here demonstrate the effects of EQ101 and EQ102 in the modulation of important biology relevant to several autoimmune and inflammatory diseases.
  • In addition, an approximate two-fold reduction of the cytotoxic NK cell population was observed with EQ101 and EQ102 treatments.

EQS-News: Defence Therapeutics Inc.: BREAKTHROUGH RESULTS WITH ACCUM(TM) A1-REPROGRAMMED MSC, MESENCHYMAL STEM CELLS, IN A NOVEL VACCINE CURED 80% OF ANIMALS WITH PRE-ESTABLISHED LYMPHOMA

Retrieved on: 
Wednesday, September 21, 2022
Control, MSC, CMC, CTLS, Engineering, ADC, Catastrophic illness, Stem cell, News, Vaccination, Company, Universal, Melanoma, Therapy, Forward-looking statement, Neoplasm, Hand, Patient, Cancer, EQS, CEO, CSE, Technology, Universitate metro station, Vaccine, Cell, Doctor of Philosophy, McGill University, Degenerative disease, Antigen presentation, Research, Animal, Infection, Security (finance), Pharmaceutical industry, BC, Defense

Defence Therapeutics Inc.: BREAKTHROUGH RESULTS WITH ACCUM(TM) A1-REPROGRAMMED MSC, MESENCHYMAL STEM CELLS, IN A NOVEL VACCINE CURED 80% OF ANIMALS WITH PRE-ESTABLISHED LYMPHOMA

Key Points: 
  • Defence Therapeutics Inc.: BREAKTHROUGH RESULTS WITH ACCUM(TM) A1-REPROGRAMMED MSC, MESENCHYMAL STEM CELLS, IN A NOVEL VACCINE CURED 80% OF ANIMALS WITH PRE-ESTABLISHED LYMPHOMA
    The issuer is solely responsible for the content of this announcement.
  • By reprogramming innate Mesenchymal Stem Cells (MSCs) to behave as antigen presenting cells, the Defence team was able to cure animals with pre-established lymphoma.
  • Defences novel breakthrough vaccine presents itself an "off-the-shelf Universal vaccine (e.g.
  • The results are that all animals survived the therapy, the great majority, 80%, of these animals rejected the tumor and remain tumor free.

DGAP-News: Defence Therapeutics Inc.:  BREAKTHROUGH DISCOVERY: DEFENCE’S ACCUMTM VARIANT 'A1' CONVERTS MESENCHYMAL STROMAL CELLS INTO POTENT ANTIGEN PRESENTING CELLS SUITABLE FOR CANCER VACCINATION

Retrieved on: 
Wednesday, August 17, 2022
Immunity, DC, ADC, ARM, Survival, APC, Unfolded protein response, GLP, Gene, Inflammation, CEO, Forward-looking statement, Catastrophic illness, A1, Technology, Cancer, Clinical trial, DGAP, B cell, Patient, Engineering, Therapy, Cell, Company, Infection, CTL, Vaccine, News, Control, Microsoft, CTLS, CSE, Melanoma, Endoplasmic reticulum stress in beta cells, Wild Arms, Animal, Antigen, Immune system, Security (finance), Pharmaceutical industry, BC, Defense

With respect to cancer, the immune system relies on dendritic cells (DCs), a subset of potent endogenous APCs, to prime cytotoxic T lymphocytes (CTLs).

Key Points: 
  • With respect to cancer, the immune system relies on dendritic cells (DCs), a subset of potent endogenous APCs, to prime cytotoxic T lymphocytes (CTLs).
  • Unfortunately, however, most cancer cells can acquire strategies to escape DC-elicited immunity resulting in the development of deadly tumors.
  • To overcome this issue, Defence Therapeutics applied a novel strategy, which consists at reprogramming the immune-suppressive MSCs to convert them into potent APCs.
  • This application discovered that it uses a unique cell type to which tumor cells are not programmed to respond.

CellChorus Publishes Data Demonstrating the Importance of T Cell Immunity in SARS-CoV-2

Retrieved on: 
Monday, March 21, 2022
Technology, Research, Infectious Diseases, Software, Biotechnology, Health, Pharmaceutical, Data Management, Science, Virus, Cell, University, Epitope, Manuscript, Multimedia, CTLS, Vaccine, B cell, Research, BioTechniques, Commercial, Achievement, Severe acute respiratory syndrome coronavirus 2, Immunity, Intelligence, RNA, CEO, Time, Fluorescence-lifetime imaging microscopy, Phenotype, COVID, NK, Flow cytometry, Peptide, Infection

View the full release here: https://www.businesswire.com/news/home/20220321005079/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220321005079/en/
    Commercial vaccines seek sterilizing immunity by generating neutralizing antibodies that can protect against viruses like SARS-CoV-2.
  • The manuscript is based on research completed by scientists at CellChorus and the University of Houston.
  • The development and performance of COVID vaccines has been a great achievement, said Daniel Meyer, CEO of CellChorus.
  • CellChorus is the leader in applying artificial intelligence to visually evaluate how thousands of individual immune cells, such as T cells and NK cells, perform over time.

Tevogen Bio Accelerates Growth With New Corporate Hub to Accommodate its Expanding Operations

Retrieved on: 
Monday, February 7, 2022
Research, Other Health, Pharmaceutical, Oncology, Infectious Diseases, Hospitals, Genetics, Clinical Trials, Science, Biotechnology, Stem Cells, Health, Other Science, Investigator's brochure, CTL, Intellectual property, Multimedia, Medicine, Research, Intention, Multiple sclerosis, Company, Thomas Jefferson University Hospital, Degenerative disease, Leadership, Clinical trial, Efficiency, Infection, FDA, EBV, Patient, Epstein–Barr virus, Severe acute respiratory syndrome coronavirus 2, Population, Bio, MS, Ecosystem, CTLS, Cancer, COVID-19, Pharmaceutical industry, Vaccine, Tevogen’s T cell Technology, Investigational COVID-19 Therapy and Pipeline Targets, Tevogen Bio, TEVOGEN’S T CELL TECHNOLOGY, INVESTIGATIONAL COVID-19 THERAPY AND PIPELINE TARGETS, TEVOGEN BIO

View the full release here: https://www.businesswire.com/news/home/20220207005866/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220207005866/en/
    Tevogen Bio new corporate hub, Warren NJ (Photo: Business Wire)
    The facility, located in New Jerseys biotech corridor, will serve as the companys central location for corporate operations and was selected after thorough countrywide market research.
  • Tevogen CEO Ryan Saadi , M.D., M.P.H., said, Our corporate hub represents an important operational next step to best strategically support the diversification and expansion of our portfolio of T cell immunotherapies.
  • Tevogen Bio is driven by a team of distinguished scientists and highly experienced biopharmaceutical leaders who have successfully developed and commercialized multiple franchises.
  • This press release contains certain forward-looking statements relating to Tevogen Bio Inc.s (the Company) development and patient access of its innovations in infectious diseases and oncology.

Tevogen Bio Announces Positive Safety Data from Second Cohort in Ongoing Proof-of-Concept Clinical Trial of TVGN-489, its Investigational T cell Therapy for Treatment of COVID-19 in High-Risk Patients

Retrieved on: 
Thursday, February 3, 2022
Health, Infectious Diseases, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Standard of care, Safety, Principal, Degenerative disease, Patient, Infection, Toxic epidermal necrolysis, Clinical trial, Omicron, Clinical research, CTL, Immunotherapy, CTLS, COVID-19, Jefferson Health, Adult, Medicine, Company, Cytokine release syndrome, Bio, CRS, Thomas Jefferson University Hospital, Severe acute respiratory syndrome coronavirus 2, FDA, Therapy, Arm, Pharmaceutical industry, Vaccine, TVGN-489, Tevogen Bio, TVGN-489, TEVOGEN BIO

The dosing of patients on dose levels one and two marks the midway point of the trials planned four dosing levels.

Key Points: 
  • The dosing of patients on dose levels one and two marks the midway point of the trials planned four dosing levels.
  • The trial is enrolling participants at high risk of severe COVID-19 progression due to advanced age or other underlying health conditions.
  • The outcomes of participants receiving the investigational therapy (Arm A) are being compared to patients receiving standard of care (Arm B).
  • Investigators are currently enrolling the third cohort of patients who will receive a higher dose level of TVGN-489 via infusion.

NanoPass's intradermal delivery platform used in Emergex's next generation COVID-19 vaccination study

Retrieved on: 
Wednesday, January 26, 2022
COVID-19, Federal Food, Drug, and Cosmetic Act, Needle, CE, Volunteering, Skin, Dengue fever, RNA transfection, CTLS, Syringe, COVID, Biotechnology, Immunity, FDA, Lymphocyte, Vaccination, Peptide, Virus, Temperature, CEO, NES, Severe acute respiratory syndrome coronavirus 2, Gold, Antigen, Safety, Disease, Vaccine, Protein, Coronavirus

During the double-blind, randomised and comparator-controlled study of two groups of 13 volunteers at high and low doses, subjects will be injected using NanoPass's intradermal delivery platform, MicronJet 600.

Key Points: 
  • During the double-blind, randomised and comparator-controlled study of two groups of 13 volunteers at high and low doses, subjects will be injected using NanoPass's intradermal delivery platform, MicronJet 600.
  • According to Emergex, the vaccine may also offer broad immunity against SARS-CoV-1 and all SARS-CoV-2 variants and provide long-lasting immunity that does not require seasonal booster vaccines.
  • NanoPass is a pioneer in the development and commercialization of microneedle-based delivery platforms for aesthetics, vaccines and more.
  • It is supported by extensive clinical data and approved for the delivery of any substance or drug under the surface of the skin that is approved for this delivery route.